This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Jefferies Keeps Their Buy Rating on Sanofi (SNYNF)
Jefferies analyst Michael Leuchten maintained a Buy rating on Sanofi today and set a price target of €100.00.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Leuchten covers the Healthcare sector, focusing on stocks such as Novo Nordisk, GlaxoSmithKline, and Roche Holding AG. According to TipRanks, Leuchten has an average return of -4.7% and a 50.44% success rate on recommended stocks.
In addition to Jefferies, Sanofi also received a Buy from Deutsche Bank ‘s Emmanuel Papadakis in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Sanofi (Other OTC: SNYNF).
SNYNF market cap is currently €96.39B and has a P/E ratio of 12.92.
Read More on SNYNF:
Disclaimer & DisclosureReport an Issue
- Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
- Sanofi’s Amlitelimab Eczema Trial Reaches Completion, Setting Up a Key Pipeline Catalyst
- Sanofi initiated with an Outperform at Bernstein
- Trump Trade: President issues short-term waiver of Jones Act
- Trump claims TrumpRx website offers lowest prices, review says not so, NYT says
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
